CD4 and neoplasm: Pro- or anti-tumor dichotomy has also been applied to DCs, since conventional DC 1(CDC1) may cross-present tumor antigens to CD8 T cells with tumor-killing potential, and CDC2 stimulate CD4 T cells that could promote or impede anti-tumor responses [10,11].